FDA's Final Rule On IND Safety Reporting Encourages More Limited Submissions
This article was originally published in The Pink Sheet Daily
Executive Summary
Revisions emphasize the types of evidence that suggest a causal relationship between the drug and adverse event.
You may also be interested in...
Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”
Draft guidance from FDA would adopt the International Conference on Harmonization’s periodic benefit-risk evaluation reports, which will offer sponsors the opportunity to provide updates on benefit information along with safety signals to the regulatory authorities.